<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">
placeholder

Dr. Kim on Tislelizumab in Advanced ESCC

Written by OncLive on February 23, 2023

Sunnie Kim, assistant professor, medicine — medical oncology, University of Colorado Anschutz Medical Campus, contextualizes the use of tislelizumab (BGB-A317) as a frontline treatment option in advanced esophageal squamous cell carcinoma (ESCC).

Topics: Press Coverage

Related Stories